UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $25.00 price target on the stock.

URGN has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. Oppenheimer restated an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $43.70.

UroGen Pharma Price Performance

UroGen Pharma stock opened at $10.37 on Wednesday. UroGen Pharma has a 12 month low of $9.78 and a 12 month high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business has a 50 day simple moving average of $10.92 and a 200-day simple moving average of $12.41.

Insider Transactions at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in UroGen Pharma during the third quarter worth about $179,000. Wesbanco Bank Inc. purchased a new stake in shares of UroGen Pharma during the 3rd quarter valued at approximately $945,000. China Universal Asset Management Co. Ltd. lifted its holdings in UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after acquiring an additional 3,856 shares during the last quarter. Rice Hall James & Associates LLC grew its position in UroGen Pharma by 273.6% in the third quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock worth $3,453,000 after acquiring an additional 199,110 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in UroGen Pharma during the third quarter worth $249,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.